Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

The PSMA targeting ligand in Pluvicto™, is chemically attached to a therapeutic radioactive atom called Lutetium-177 (177Lu), which releases an energetic beta particle to precisely deliver cell ...

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...

Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with ...

Older adults and middle-aged adults are more at risk of developing cancer, and dying from the deadly disease in India ...

(Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto� (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients with prostate-specific membrane ...